J. Virol., 05 1996, 2825-2831, Vol 70, No. 5
Copyright © 1996, American Society for Microbiology

Anti-human immunodeficiency virus type 1 activity of an oligocationic compound mediated via gp120 V3 interactions

WA O'Brien, M Sumner-Smith, SH Mao, S Sadeghi, JQ Zhao and IS Chen
Department of Medicine, West Los Angeles Veterans Affairs Medical Center, California, USA.

An oligocationic peptide compound (ALX40-4C) was developed for consideration in the treatment of human immunodeficiency virus type 1 (HIV-1) infection. This compound was designed to mimic the basic domain of the HIV-1 transactivation protein, Tat, and will competitively inhibit Tat binding to its specific RNA hairpin target (TAR [transactivation region]), found at the 5' end of all HIV-1 transcripts. Blocking Tat-TAR interactions can abrogate HIV-1 replication. ALX40-4C was shown to inhibit replication of HIV-1NL4-3 in a range of cell types, including primary cells and transformed cell lines, by as much as 10(4)-fold. In some experiments, virus rescue was not possible even after removal of ALX40-4C from the cultures. Strain- dependent resistance has been demonstrated for all antiretroviral agents tested; therefore, we tested for variable sensitivity to ALX40- 4C. The cloned primary strains, HIV-JR-CSF and HIV-JR-FL, were less sensitive to ALX40-4C inhibition. Unexpectedly, determinants for efficient ALX40-4C inhibition were mapped by using recombinant virus strains to the V3 region of gpl20 and were shown to act at early events in viral replication, which include viral entry. If entry and reverse transcription are bypassed by transfection, a more modest, virus strain- independent inhibition is shown; this inhibition is likely due to blocking of Tat-TAR interaction. Thus, the highly basic oligocationic Tat inhibitor ALX40-4C appears to interfere with initial virus-target cell interactions which involve HIV-1 gp120 V3 determinants, most efficiently for T-cell line-adapted strains.

This article has been cited by other articles:

• Huang, M.-B., Jin, L. L., James, C. O., Khan, M., Powell, M. D., Bond, V. C. (2004). Characterization of Nef-CXCR4 Interactions Important for Apoptosis Induction. J. Virol. 78: 11084-11096 [Abstract] [Full Text]  
• Bachelder, R. E., Wendt, M. A., Mercurio, A. M. (2002). Vascular Endothelial Growth Factor Promotes Breast Carcinoma Invasion in an Autocrine Manner by Regulating the Chemokine Receptor CXCR4. Cancer Res. 62: 7203-7206 [Abstract] [Full Text]  
• Said, E. A., Krust, B., Nisole, S., Svab, J., Briand, J.-P., Hovanessian, A. G. (2002). The Anti-HIV Cytokine Midkine Binds the Cell Surface-expressed Nucleolin as a Low Affinity Receptor. J. Biol. Chem. 277: 37492-37502 [Abstract] [Full Text]  
• Kaushik, N., Basu, A., Palumbo, P., Myers, R. L., Pandey, V. N. (2002). Anti-TAR Polyamide Nucleotide Analog Conjugated with a Membrane-Permeating Peptide Inhibits Human Immunodeficiency Virus Type 1 Production. J. Virol. 76: 3881-3891 [Abstract] [Full Text]  
• Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Zhang, Z., O'Brien, W. A., Ratner, L., Shaw, G. M., Hunter, E. (2001). Sensitivity of Human Immunodeficiency Virus Type 1 to Fusion Inhibitors Targeted to the gp41 First Heptad Repeat Involves Distinct Regions of gp41 and Is Consistently Modulated by gp120 Interactions with the Coreceptor. J. Virol. 75: 8605-8614 [Abstract] [Full Text]  
• Dragic, T. (2001). An overview of the determinants of CCR5 and CXCR4 co-receptor function. J. Gen. Virol. 82: 1807-1814 [Full Text]  
• Derdeyn, C. A., Decker, J. M., Sfakianos, J. N., Wu, X., O'Brien, W. A., Ratner, L., Kappes, J. C., Shaw, G. M., Hunter, E. (2000). Sensitivity of Human Immunodeficiency Virus Type 1 to the Fusion Inhibitor T-20 Is Modulated by Coreceptor Specificity Defined by the V3 Loop of gp120. J. Virol. 74: 8358-8367 [Abstract] [Full Text]  
• Doranz, B. J., Orsini, M. J., Turner, J. D., Hoffman, T. L., Berson, J. F., Hoxie, J. A., Peiper, S. C., Brass, L. F., Doms, R. W. (1999). Identification of CXCR4 Domains That Support Coreceptor and Chemokine Receptor Functions. J. Virol. 73: 2752-2761 [Abstract] [Full Text]  
• Suzuki, Y., Koyanagi, Y., Tanaka, Y., Murakami, T., Misawa, N., Maeda, N., Kimura, T., Shida, H., Hoxie, J. A., O'Brien, W. A., Yamamoto, N. (1999). Determinant in Human Immunodeficiency Virus Type 1 for Efficient Replication under Cytokine-Induced CD4+ T-Helper 1 (Th1)- and Th2-Type Conditions. J. Virol. 73: 316-324 [Abstract] [Full Text]  
• Dealwis, C., Fernandez, E. J., Thompson, D. A., Simon, R. J., Siani, M. A., Lolis, E. (1998). Crystal structure of chemically synthesized [N33A] stromal cell-derived factor 1alpha , a potent ligand for the HIV-1 "fusin" coreceptor. Proc. Natl. Acad. Sci. USA 95: 6941-6946 [Abstract] [Full Text]  
• Doranz, B. J., Grovit-Ferbas, K., Sharron, M. P., Mao, S.-H., Goetz, M. B., Daar, E. S., Doms, R. W., O'Brien, W. A. (1997). A Small-molecule Inhibitor Directed against the Chemokine Receptor CXCR4 Prevents its Use as an HIV-1 Coreceptor. J. Exp. Med. 186: 1395-1400 [Abstract] [Full Text]